Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

PURPOSE: Although patients with newly diagnosed WHO grade 3 malignant glioma have a more favorable prognosis than those with WHO grade 4 malignant glioma, salvage therapies following recurrence offer essentially palliative benefit. We did a phase II trial of bevacizumab, a monoclonal antibody to vas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Desjardins, Annick, Reardon, David A., Herndon, James E., Marcello, Jennifer, Quinn, Jennifer A., Rich, Jeremy N., Sathornsumetee, Sith, Gururangan, Sridharan, Sampson, John, Bailey, Leighann, Bigner, Darell D., Friedman, Allan H., Friedman, Henry S., Vredenburgh, James J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3671765/
https://ncbi.nlm.nih.gov/pubmed/18981004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0260
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados